Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

17. ledna 2018 aktualizováno: Children's Oncology Group

A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it is no longer present by conventional imaging and tumor markers from serum and cerebrospinal fluid. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Combining different types of therapy may kill more tumor cells.

PURPOSE: This Phase II trial is studying how well neoadjuvant chemotherapy with or without surgery and with or without high dose chemotherapy and peripheral stem cell transplantation, can increase response rates prior to radiation therapy and increase progression free and overall surviving patients with newly diagnosed intracranial germ cell tumors.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

OBJECTIVES:

  • Determine the response rate of patients with non-germinomatous germ cell tumors treated with neoadjuvant chemotherapy.
  • Determine the progression-free survival and overall survival of patients treated with neoadjuvant chemotherapy with or without second-look surgery followed by radiotherapy with or without autologous peripheral blood stem cell transplantation (PBSCT).
  • Determine whether additional complete responses can be achieved after high-dose thiotepa and etoposide with PBSCT in patients with persistently positive markers, histological evidence of residual malignant elements, or unresectable residual tumors after initial neoadjuvant chemotherapy.
  • Determine patterns of recurrence in patients treated with this regimen.
  • Correlate tumor marker response with radiographic and clinical measures of response, as well as findings at second-look surgery in patients with radiological evidence of residual disease.

OUTLINE:

  • Induction chemotherapy:

    • Courses 1, 3, and 5: Patients receive carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1-3. Beginning on day 4, patients receive filgrastim (G-CSF) IV or subcutaneously (SC) for 10 days or until blood counts recover. Courses are 3 weeks in duration.
    • Courses 2, 4, and 6: Patients receive etoposide IV over 1 hour followed by ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive G-CSF IV or SC for 10 days or until blood counts recover. Courses are 3 weeks in duration.

Patients undergo re-evaluation. Patients with a complete response (CR) go directly to radiotherapy. Approximately 3 weeks after completion of induction chemotherapy, all patients with less than a CR are encouraged to undergo second-look surgery.

After second-look surgery, patients with a CR or a partial response (PR) go directly to radiotherapy. Patients with less than a PR undergo consolidation chemotherapy with peripheral blood stem cell rescue (PBSC) followed by radiotherapy.

  • Consolidation chemotherapy: Patients undergo PBSC collection. Patients receive G-CSF SC until PBSC collection is complete. Patients then receive thiotepa IV over 3 hours followed by etoposide IV over 3 hours on days -5 to -3. PBSCs are reinfused on day 0. Beginning on day 1 and continuing until blood counts recover, patients receive G-CSF SC daily.
  • Radiotherapy: All patients receive radiotherapy once daily 5 days a week for 5-6 weeks beginning after recovery from induction chemotherapy or second-look surgery or within 9 weeks after PBSC reinfusion.

Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.

PROJECTED ACCRUAL: A total of 80-100 patients will be accrued for this study within 36-42 months.

Typ studie

Intervenční

Zápis (Aktuální)

104

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Austrálie
    • Queensland
      • Brisbane, Queensland, Austrálie, 4029
        • Royal Children's Hospital
    • Victoria
      • Parkville, Victoria, Austrálie, 3052
        • Royal Children's Hospital
    • Western Australia
      • Perth, Western Australia, Austrálie, 6001
        • Princess Margaret Hospital for Children
  • Kanada
      • Quebec, Kanada, G1V 4G2
        • Centre Hospitalier Universitaire de Quebec
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • Children's & Women's Hospital of British Columbia
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
        • Janeway Children's Health and Rehabilitation Centre
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3K 6R8
        • IWK Health Centre
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster Children's Hospital at Hamilton Health Sciences
      • Toronto, Ontario, Kanada, M5G 1X8
        • Hospital for Sick Children
    • Quebec
      • Montreal, Quebec, Kanada, H3H 1P3
        • Montreal Children's Hospital at McGill University Health Center
      • Montreal, Quebec, Kanada, H3T 1C5
        • Hopital Sainte Justine
    • Saskatchewan
      • Saskatoon, Saskatchewan, Kanada, S7N 4H4
        • Saskatoon Cancer Centre at the University of Saskatchewan
  • Nový Zéland
      • Auckland, Nový Zéland, 1
        • Starship Children's Health
      • Christchurch, Nový Zéland
        • Christchurch Hospital
  • Spojené státy
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35294
        • Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
    • Arizona
      • Phoenix, Arizona, Spojené státy, 85016-7710
        • Phoenix Children's Hospital
    • Arkansas
      • Little Rock, Arkansas, Spojené státy, 72205
        • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
    • California
      • Downey, California, Spojené státy, 90242-2814
        • Southern California Permanente Medical Group
      • Loma Linda, California, Spojené státy, 92354
        • Loma Linda University Cancer Institute at Loma Linda University Medical Center
      • Long Beach, California, Spojené státy, 90801
        • Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
      • Los Angeles, California, Spojené státy, 90027
        • Childrens Hospital Los Angeles
      • Madera, California, Spojené státy, 93638-8762
        • Children's Hospital Central California
      • Oakland, California, Spojené státy, 94609
        • Children's Hospital and Research Center Oakland
      • Orange, California, Spojené státy, 92868
        • Children's Hospital of Orange County
      • Sacramento, California, Spojené státy, 95816
        • Sutter Cancer center
      • San Diego, California, Spojené státy, 92123-4282
        • Rady Children's Hospital - San Diego
      • San Francisco, California, Spojené státy, 94115
        • UCSF Helen Diller Family Comprehensive Cancer Center
      • Stanford, California, Spojené státy, 94305-5824
        • Stanford Cancer Center
    • Connecticut
      • Farmington, Connecticut, Spojené státy, 06360-2875
        • Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    • Delaware
      • Wilmington, Delaware, Spojené státy, 19803
        • Alfred I. DuPont Hospital for Children
    • District of Columbia
      • Washington, District of Columbia, Spojené státy, 20010-2970
        • Children's National Medical Center
    • Florida
      • Fort Myers, Florida, Spojené státy, 33901
        • Lee Cancer Care of Lee Memorial Health System
      • Gainesville, Florida, Spojené státy, 32610-0232
        • University of Florida Shands Cancer Center
      • Jacksonville, Florida, Spojené státy, 32207
        • Nemours Children's Clinic
      • Miami, Florida, Spojené státy, 33136
        • University of Miami Sylvester Comprehensive Cancer Center - Miami
      • Miami, Florida, Spojené státy, 33155
        • Miami Children's Hospital
      • Orlando, Florida, Spojené státy, 32803-1273
        • Florida Hospital Cancer Institute at Florida Hospital Orlando
      • Pensacola, Florida, Spojené státy, 32504
        • Sacred Heart Cancer Center at Sacred Heart Hospital
      • Saint Petersburg, Florida, Spojené státy, 33701
        • All Children's Hospital
      • Tampa, Florida, Spojené státy, 33607
        • St. Joseph's Cancer Institute at St. Joseph's Hospital
      • West Palm Beach, Florida, Spojené státy, 33407
        • Kaplan Cancer Center at St. Mary's Medical Center
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30322
        • Winship Cancer Institute of Emory University
      • Augusta, Georgia, Spojené státy, 30912-3730
        • MBCCOP - Medical College of Georgia Cancer Center
    • Illinois
      • Chicago, Illinois, Spojené státy, 60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
      • Chicago, Illinois, Spojené státy, 60637-1470
        • University of Chicago Cancer Research Center
      • Park Ridge, Illinois, Spojené státy, 60068-1174
        • Advocate Lutheran General Cancer Care Center
      • Springfield, Illinois, Spojené státy, 62794-9677
        • Simmons Cooper Cancer Institute
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46202-5289
        • Indiana University Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, Spojené státy, 46260
        • St. Vincent Indianapolis Hospital
    • Kansas
      • Kansas City, Kansas, Spojené státy, 66160-7357
        • Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21231-2410
        • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
        • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
      • Boston, Massachusetts, Spojené státy, 02111
        • Floating Hospital for Children at Tufts - New England Medical Center
    • Michigan
      • Detroit, Michigan, Spojené státy, 48201-1379
        • Barbara Ann Karmanos Cancer Institute
      • Grand Rapids, Michigan, Spojené státy, 49503-2560
        • Butterworth Hospital at Spectrum Health
      • Grosse Pointe Woods, Michigan, Spojené státy, 48236
        • Van Elslander Cancer Center at St. John Hospital and Medical Center
      • Lansing, Michigan, Spojené státy, 48910
        • Breslin Cancer Center at Ingham Regional Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55404
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
      • Minneapolis, Minnesota, Spojené státy, 55455
        • Masonic Cancer Center at University of Minnesota
      • Rochester, Minnesota, Spojené státy, 55905
        • Mayo Clinic Cancer Center
    • Mississippi
      • Jackson, Mississippi, Spojené státy, 39216-4505
        • University of Mississippi Cancer Clinic
    • Missouri
      • Kansas City, Missouri, Spojené státy, 64108
        • Children's Mercy Hospital
      • Saint Louis, Missouri, Spojené státy, 63110
        • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
    • New Jersey
      • Hackensack, New Jersey, Spojené státy, 07601
        • Hackensack University Medical Center Cancer Center
      • New Brunswick, New Jersey, Spojené státy, 08903
        • Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
      • Newark, New Jersey, Spojené státy, 07112
        • Newark Beth Israel Medical Center
      • Paterson, New Jersey, Spojené státy, 07503
        • St. Joseph's Hospital and Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Spojené státy, 87131-5636
        • University of New Mexico Cancer Center
    • New York
      • Bronx, New York, Spojené státy, 10461
        • Albert Einstein Cancer Center at Albert Einstein College of Medicine
      • New York, New York, Spojené státy, 10016
        • NYU Cancer Institute at New York University Medical Center
      • New York, New York, Spojené státy, 10032
        • Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
      • Syracuse, New York, Spojené státy, 13210
        • SUNY Upstate Medical University Hospital
      • Valhalla, New York, Spojené státy, 10595
        • New York Medical College
    • North Carolina
      • Charlotte, North Carolina, Spojené státy, 28232-2861
        • Blumenthal Cancer Center at Carolinas Medical Center
      • Durham, North Carolina, Spojené státy, 27710
        • Duke Comprehensive Cancer Center
    • Ohio
      • Akron, Ohio, Spojené státy, 44308-1062
        • Akron Children's Hospital
      • Cincinnati, Ohio, Spojené státy, 45229-3039
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Spojené státy, 44195
        • Cleveland Clinic Taussig Cancer Center
      • Columbus, Ohio, Spojené státy, 43205-2696
        • Nationwide Children's Hospital
      • Dayton, Ohio, Spojené státy, 45404-1815
        • Children's Medical Center - Dayton
    • Oklahoma
      • Oklahoma City, Oklahoma, Spojené státy, 73104
        • Oklahoma University Cancer Institute
    • Oregon
      • Portland, Oregon, Spojené státy, 97239-3098
        • Oregon Health and Science University Cancer Institute
    • Pennsylvania
      • Hershey, Pennsylvania, Spojené státy, 17033-0850
        • Penn State Cancer Institute at Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, Spojené státy, 19134-1095
        • St. Christopher's Hospital for Children
      • Philadelphia, Pennsylvania, Spojené státy, 19104-9786
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
        • Children's Hospital of Pittsburgh
    • Rhode Island
      • Providence, Rhode Island, Spojené státy, 02903
        • Rhode Island Hospital Comprehensive Cancer Center
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29425
        • Hollings Cancer Center at Medical University of South Carolina
    • South Dakota
      • Sioux Falls, South Dakota, Spojené státy, 57117-5039
        • Sanford Cancer Center at Sanford USD Medical Center
    • Tennessee
      • Memphis, Tennessee, Spojené státy, 38105
        • St. Jude Children's Research Hospital
      • Nashville, Tennessee, Spojené státy, 37232-6838
        • Vanderbilt-Ingram Cancer Center
    • Texas
      • Austin, Texas, Spojené státy, 78723
        • Dell Children's Medical Center of Central Texas
      • Corpus Christi, Texas, Spojené státy, 78411
        • Driscoll Children's Hospital
      • Dallas, Texas, Spojené státy, 75390
        • Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
      • Fort Worth, Texas, Spojené státy, 76104
        • Cook Children's Medical Center - Fort Worth
      • Lubbock, Texas, Spojené státy, 79410
        • Covenant Children's Hospital
      • San Antonio, Texas, Spojené státy, 78229-3993
        • Methodist Children's Hospital of South Texas
      • San Antonio, Texas, Spojené státy, 78207
        • University of Texas Health Science Center at San Antonio
    • Utah
      • Salt Lake City, Utah, Spojené státy, 84113-1100
        • Primary Children's Medical Center
    • Virginia
      • Norfolk, Virginia, Spojené státy, 23507-1971
        • Children's Hospital of The King's Daughters
    • West Virginia
      • Charleston, West Virginia, Spojené státy, 25302
        • West Virginia University Health Sciences Center - Charleston
    • Wisconsin
      • Green Bay, Wisconsin, Spojené státy, 54307-3508
        • St. Vincent Hospital Regional Cancer Center
      • Marshfield, Wisconsin, Spojené státy, 54449
        • Marshfield Clinic - Marshfield Center
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Midwest Children's Cancer Center
  • Švýcarsko
      • Bern, Švýcarsko, 3010
        • Swiss Pediatric Oncology Group Bern
      • Geneva, Švýcarsko, 1205
        • Swiss Pediatric Oncology Group Geneva

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

3 roky až 24 let (Dítě, Dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

DISEASE CHARACTERISTICS:

  • One of the following diagnoses:

    • Histologically confirmed intracranial non-germinomatous germ cell tumor (NGGCT) of 1 of the following types:

      • Endodermal sinus tumor (yolk sac tumor)
      • Embryonal carcinoma
      • Choriocarcinoma
      • Immature teratoma and teratoma with malignant transformation
      • Mixed germ cell tumor
    • Histologically confirmed germinoma with elevation of serum/CSF beta human chorionic gonadotropin (HCG) levels greater than 50 mIU/mL or any serum/CSF alpha-fetoprotein (AFP) levels greater than 10 ng/ml or above institutional norm
    • Histologically unconfirmed pineal and/or suprasellar tumors with serum/CSF beta HCG levels greater than 50 mIU/mL or AFP levels greater than 10 ng/ml or above institutional norm
  • Patients with normal AFP and beta HCG < 50 mIU/mL without histologic diagnosis of a NGGCT or patients with pure germinoma without elevation of tumor marker are ineligible
  • Initial diagnosis within the past 31 days

PATIENT CHARACTERISTICS:

Age

  • 3 to 24 at diagnosis

Performance status

  • No minimum performance level

Life expectancy

  • At least 8 weeks

Hematopoietic

  • Absolute neutrophil count at least 1,000/mm^3
  • Platelet count at least 100,000/mm^3 (transfusion independent)
  • Hemoglobin at least 10.0 g/dL (transfusion allowed)

Hepatic

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • ALT no greater than 2.5 times ULN

Renal

  • Creatinine no greater than 1.5 times ULN OR
  • Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min

Pulmonary

  • No assisted ventilation

Other

  • Seizure disorders allowed
  • No patients in status or coma
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patient must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Prior corticosteroids allowed
  • Concurrent corticosteroids allowed
  • Concurrent endocrine replacement therapy allowed (e.g., L-thyroxine, testosterone, estrogen, desmopressin acetate)
  • No concurrent growth hormone therapy

Radiotherapy

  • Not specified

Surgery

  • More than 1 prior surgery allowed

Other

  • No other prior therapy for malignancy

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Radiation Therapy (CR from Induction)
Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC > 750/L and platelets > 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
Postup: adjuvantní terapie
Postup: neoadjuvantní terapii
Postup: konvenční chirurgie
Postup: transplantace kmenových buněk periferní krve
Lék: etoposid
Vzhledem k tomu, IV
Ostatní jména:
  • VP-16
  • Etopophos
  • VePesid
  • NSC #141540
Lék: karboplatina
Vzhledem k tomu, IV
Ostatní jména:
  • Paraplatin
  • NSC #241240
Lék: thiotepa
Vzhledem k tomu, IV
Ostatní jména:
  • Thiofosfamid
  • Tespa
  • Triethylenthiofosforamid Tspa
  • WR-45312
  • NSC #6396
Lék: ifosfamid
Vzhledem k tomu, IV
Ostatní jména:
  • Ifex
  • Ifosfamid
  • Isofosfamid
  • Z4942
  • NSC #109724
Záření: radiation therapy
craniospinal irradiation
Ostatní jména:
  • Craniospinal irradiation (CSI) followed by boost radiation to the sites of gross disease at diagnosis.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Response to Induction Chemotherapy
Časové okno: 18 weeks
A patient who achieves a complete or partial response, defined a reduction of at least 65% in tumor size after induction chemotherapy will be considered to have experienced response.
18 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
The Probability of Event-free Survival (EFS)
Časové okno: At 3 years from study entry
Event-free Survival was defined as time from study entry to death from any cause, disease progression or recurrence, or second malignant neoplasm. Event-free survival was estimated by KM estimate.
At 3 years from study entry
Progression-free Survival (PFS)
Časové okno: At 3 years from study entry
Progression-free Survival was defined as time from study entry to disease progression or recurrence. Deaths that are clearly unrelated to disease progression, and second neoplasms are censored in this analysis. Progression -free survival was estimated by KM estimate.
At 3 years from study entry
Overall Survival (OS)
Časové okno: At 3 years from study entry
Overall Survival was defined as time from study entry to death from any cause. Overall survival was estimated by KM estimate.
At 3 years from study entry
Number of Patients Experiencing Toxic Death
Časové okno: During chemotherapy (up to 18 weeks)
Toxic death, defined as death predominantly attributable to treatment-related causes.
During chemotherapy (up to 18 weeks)
Occurrence of Non-hematological Grade 4 Toxicity Occurrence of Nonhematological Grade 4 Toxicity
Časové okno: During chemotherapy(up to 18 weeks)
The number of patients who experienced non-hematological grade 4 toxicities anytime during chemotherapy.
During chemotherapy(up to 18 weeks)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Children's Oncology Group

Spolupracovníci

National Cancer Institute (NCI)

Vyšetřovatelé

  • Studijní židle: Stewart Goldman, MD, Ann & Robert H Lurie Children's Hospital of Chicago

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. ledna 2004

Primární dokončení (Aktuální)

1. února 2009

Dokončení studie (Aktuální)

1. února 2009

Termíny zápisu do studia

První předloženo

3. října 2002

První předloženo, které splnilo kritéria kontroly kvality

26. ledna 2003

První zveřejněno (Odhad)

27. ledna 2003

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

14. února 2018

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. ledna 2018

Naposledy ověřeno

1. ledna 2018

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • ACNS0122
  • CDR0000257664 (Jiný identifikátor: Clinical Trials.gov)
  • COG-ACNS0122 (Jiný identifikátor: Children's Oncology Group)

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Mozkový nádor

Klinické studie na adjuvantní terapie

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Malta

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit